We have superior data. Catch-up will happen Hard for any of us to envision higher share price despite all our beliefs that this technology should be valued much higher. The official signal by management has been set when we reached the FDA milestone of p#25 @450-days and via the Jan. 3rd article. It was though hinted in the Feb. 7 2022 corporate presentation that 2023 would be projected as a transformative year.
Before the final surge, these stocks have been battered. And take some spikes and you'll notice that a 10x spike happens quite often. For example, for IMGN:
June 2008 (140M$) - Jul 2013 (1.6B$)
Nov 2016 (160M$) - Feb 2018 (1.5B$)
May 2019 (270M$) - Feb 2021 (1.7B$)
We are starting much lower, so have ample room for upside. We simply need this big pharma partner that will believe in our ACT platform. It's their call.
https://companiesmarketcap.com/iveric-bio/marketcap/
https://companiesmarketcap.com/immunogen/marketcap/